# The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

> **NCT03173599** · PHASE1 · COMPLETED · sponsor: **Guangzhou Yipinhong Pharmaceutical CO.,LTD** · enrollment: 48 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** PNA 40mg
- **DRUG:** PNA 80mg
- **DRUG:** PNA 160mg
- **DRUG:** PNA 240mg
- **DRUG:** PNA 360mg
- **DRUG:** PNA 480mg
- **DRUG:** PNA Placebo

## Key facts

- **NCT ID:** NCT03173599
- **Lead sponsor:** Guangzhou Yipinhong Pharmaceutical CO.,LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173599, "The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03173599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*